Silexion Therapeutics Corp 8-K

What Happened
Silexion Therapeutics Corp. (Nasdaq: SLXN) announced in an 8-K filed May 26, 2026 that it will implement a 1-for-10 reverse share split of all issued and outstanding—and authorized but unissued—ordinary shares. The reverse split was approved by shareholders on May 5, 2026, becomes effective after market close on May 28, 2026, and shares will trade on a reverse-split-adjusted basis on the Nasdaq Capital Market at the open on May 29, 2026. The company’s ticker will remain "SLXN."

Key Details

• Reverse split ratio: 1-for-10 (every 10 pre-split shares → 1 post-split share).
• Effective timing: after the close of market on May 28, 2026; trading adjusts at open May 29, 2026.
• Par value change: increases from $0.0135 to $0.135 per ordinary share.
• Fractional shares: no fractional shares issued; fractional interests for DTC participants will be rounded up to the nearest whole share.
• No action required by shareholders; press release attached as Exhibit 99.1 to the 8-K.

Why It Matters
A reverse split reduces the number of outstanding shares and proportionally increases the per-share price and par value; it does not change each holder’s percentage ownership except for rounding effects. For investors, this can affect share price per share, market perception, and per-share metrics (like earnings per share), but does not alter the company’s underlying market capitalization solely by the split. The automatic rounding-up of fractional shares for DTC participants means eligible holders will receive whole shares without needing to act.